Peptide questions · ARA-290
How long does ARA-290 take to work?
Reviewed Evidence: ModeratePublished by PepVault
ARA-290’s onset is 1–2 weeks (user reports; the trials' main readouts were at day 28), its peak effect comes at 4 weeks, the point the trials measured, and its typical duration is 4 weeks, often repeated, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Four small randomized phase 2 trials (about 200 people in all), each run or co-authored by its developer, plus rat nerve-injury work. No approval anywhere.
ARA-290 week by week
The library places four of its research notes on ARA-290 on the days they cover, from day 1 to day 120: 1 on community reports, 2 on randomized trials and 1 on clinical data.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–14 (weeks 1–2) | The first two weeks: for some, the burning eases | Community report |
| Days 14–28 (weeks 2–4) | Four weeks is where the trials looked | Randomized trial |
| Days 28–56 (weeks 4–8) | What happened after the dosing stopped | Randomized trial |
| Days 56–120 (weeks 8–18) | Past the trials' window | Clinical data |

The ARA-290 timeline’s milestones
The library’s timeline for ARA-290 marks 8 points from week 1 to week 16, backed by moderate evidence overall.
- Week 1: Commonly reported: burning or tingling starting to settle inside the first one to two weeks, though plenty of people notice nothing yet
- Week 2: Works by switching on the innate repair receptor; in rats, that damped the spinal inflammation behind nerve pain for weeks after dosing stopped
- Week 3: In one trial the gap in how much pain interfered with daily life opened by the third week of dosing
- Week 4: In a sarcoidosis trial, nerve-symptom scores improved more than placebo after 28 daily doses, and the corneal nerve-fiber measure rose
- Week 5: A week after the last dose the improvement was still there in that sarcoidosis trial; pain intensity itself improved equally on placebo
- Week 8: In the diabetes trial the gap over placebo was wider four weeks after dosing ended than on the last day of it
- Week 12: Trial follow-up found the symptom gain holding about 12 weeks after the last dose, with no more drug given
- Week 16: Community runs commonly stop at four weeks and are repeated later; past 12 weeks of dosing there is no published data
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why ARA-290 takes that long
ARA-290’s half-life is about 20 minutes, so one dose is about 96.9% cleared after 1.7 hours.
Each dose of ARA-290 clears within 1.7 hours, so its level doesn’t build up from one day to the next: the weeks on the timeline come from repeated doses, not from the compound piling up in the blood.
ARA-290 against other healing & recovery compounds
The library holds an onset-and-peak timeline for 12 healing & recovery compounds, ARA-290 among them; none of the others shares its onset of 1–2 weeks (user reports; the trials' main readouts were at day 28).
| Compound | Onset | Peak effect |
|---|---|---|
| BPC-157 | 1–7 days | 2–4 weeks |
| TB-500 | 1–2 weeks | 4–6 weeks |
| GHK-Cu | 3–6 weeks | 8–12 weeks |
| KPV | 1–2 weeks | 4–6 weeks |
| Thymalin | Not established (no controlled timing data) | Not established |
| Thymogen | Not established (no controlled timing data) | Not established |
| Vilon | Not established (no controlled timing data) | Not established |
| Linaclotide | Week 1 (bowel movements) | 1–12 weeks |
| ARA-290 | 1–2 weeks (user reports; the trials' main readouts were at day 28) | 4 weeks, the point the trials measured |
| Cartalax | Days to weeks (commonly reported) | Weeks (commonly reported) |
| Teriparatide | 1–3 months (bone formation markers, spine BMD) | 18–24 months (BMD, fracture risk) |
| Abaloparatide | 1 month (bone formation markers) | 12–18 months (BMD, fracture risk) |
Questions people ask
How long does ARA-290 take to work?
ARA-290’s onset is 1–2 weeks (user reports; the trials' main readouts were at day 28), its peak effect comes at 4 weeks, the point the trials measured, and its typical duration is 4 weeks, often repeated, by the library’s timeline (backed by moderate evidence).
When does ARA-290 reach its peak effect?
By the library’s timeline, ARA-290’s peak effect comes at 4 weeks, the point the trials measured, backed by moderate evidence.
How long is ARA-290 usually run?
The library’s timeline gives ARA-290’s typical duration as 4 weeks, often repeated; its cycle note says: The published daily courses ran 28 days (three trials) and 12 weeks (the eye study).
What does the library say about the first days on ARA-290?
Its first note on ARA-290, for days 1–14 (weeks 1–2), is “The first two weeks: for some, the burning eases”, resting on community reports.